TrialESMO open2024

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.

J Ajani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.